GLP-1 News & Analysis
14 articles
Market Mood
Hims & Hers (HIMS) Reports 3% Stock Decline After Q2 Loss
Hims & Hers Health (HIMS) stock declined 3% before trimming losses on August 11, 2026. The company reported a loss of $0.37 per share in Q2, down from a profit of $0.17 per share in the same period last year, with gross margins decreasing to 64% from 76%. This performance was affected by a one-time cost of $81 million, associated with the acquisition of Eucalyptus and restructuring due to changes in their weight-loss strategy. These financial results highlight the ongoing regulatory challenges and shifts in strategy, which are significant for investors tracking the company's performance.
Read More: Hims & Hers (HIMS) Reports 3% Stock Decline After Q2 Loss
CVS Health (CVS) Earnings Report Upcoming Analysts Focus on GLP-1
CVS Health (CVS) is scheduled to report earnings soon, with analysts paying close attention to GLP-1 drug momentum. This class of medications has been gaining traction as a weight-loss treatment, potentially impacting CVS's performance. Investors are keen to see how this will influence the company's overall outlook and revenue streams. Monitoring the earnings report may help provide insights into market trends in the healthcare sector.
Read More: CVS Health (CVS) Earnings Report Upcoming Analysts Focus on GLP-1
Pague Menos Q2 2026 Reports Record Margins Amid GLP-1 Slowdown
In Q2 2026, Pague Menos reported record margins despite a slowdown in GLP-1 sales. The company achieved a profit margin of 15%, an increase from the previous quarter. This performance reflects the company's ability to adapt to market changes while managing costs effectively. The growth in margins can influence investor sentiment positively as it showcases operational efficiency. This is significant for investors as it indicates potential resilience in the company's financial health.
Read More: Pague Menos Q2 2026 Reports Record Margins Amid GLP-1 Slowdown
GLP-1 Users Return to In-Store Clothes Shopping Trips
The article discusses a trend among GLP-1 medication users returning to in-store shopping for clothes after weight loss associated with the drugs. There are observations of increased clothing purchases and trips to physical stores. This shift highlights changing consumer behavior linked to health improvements from GLP-1s. As more consumers spend money on fashion, this could positively impact companies in retail and related sectors.
Read More: GLP-1 Users Return to In-Store Clothes Shopping Trips
Galderma Reports Nearly 25% Growth Amid Botox Demand Increase
CEO Flemming Ørnskov announced that Galderma has seen nearly 25% sales growth year-on-year at constant currencies, attributed to the rising use of GLP-1 weight-loss drugs like Ozempic. Approximately one in 10 U.S. adults are now using these medications, creating strong demand for Galderma’s aesthetic products to combat facial volume loss associated with significant weight loss, informally known as 'Ozempic face.' Growth in the U.S. market was particularly notable at 32%, compared to 19% worldwide. This trend in increasing demand for cosmetic injectables may impact Galderma's market presence positively moving forward.
Read More: Galderma Reports Nearly 25% Growth Amid Botox Demand Increase
Medicare Access to GLP-1s for Weight Loss Starting July 1
Starting July 1, Medicare beneficiaries who qualify will have access to GLP-1 weight-loss drugs for a cost of $50 per month. This initiative marks a significant change in the coverage of weight management treatments for older Americans. The availability of these drugs could potentially influence the healthcare market by increasing demand for GLP-1 medications. It is important for beneficiaries to be aware of possible side effects associated with these treatments.
Read More: Medicare Access to GLP-1s for Weight Loss Starting July 1
Novo Nordisk (NVO) Stock Target Set at $47 by Goldman Sachs
Goldman Sachs has maintained its Neutral rating and $47 price target on Novo Nordisk (NVO) after meeting with the management at the 47th Annual Global Healthcare Conference on June 9. This target represents a 7% upside from the closing price of 287.25 Danish kroner on June 12, which was up 1.66% for the day. Earlier this year, Novo shares dropped to a 52-week low near $37 following disappointing trial results for its drug CagriSema. Additionally, it held a 39% market share in the U.S. obesity and diabetes GLP-1 market, compared to Eli Lilly’s 60%.
Read More: Novo Nordisk (NVO) Stock Target Set at $47 by Goldman Sachs
High-Protein Whey Shortage Drives Prices Up Amid GLP-1 Demand
The demand for high-protein whey has surged due to increased interest in wellness products and the GLP-1 medication boom. This spike has created a substantial shortage in supply, affecting nutrition companies across the market. As a result, prices are reportedly rising significantly, impacting profit margins for companies that produce whey-based products. The ongoing trend towards health and wellness further emphasizes the importance of monitoring the whey market for potential investments.
Read More: High-Protein Whey Shortage Drives Prices Up Amid GLP-1 Demand
Wegovy Maintains Market Dominance Despite Eli Lilly GLP-1 Launch
Wegovy continues to lead the GLP-1 market among weight-loss medications, despite competition from Eli Lilly's Foundayo. Specific market share percentages or sales figures were not provided. This dominance highlights Wegovy's strong brand recognition and patient preference in a growing sector. The competitive landscape for GLP-1 medications may impact market valuations for companies involved in this space, including Eli Lilly (LLY).
Read More: Wegovy Maintains Market Dominance Despite Eli Lilly GLP-1 Launch
Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
Pfizer (PFE) has reported positive results from its GLP-1 drug PF-08653944, which shows weight loss of 10% to 12% by week 28 in Phase 2b trials. This drug features a monthly injection regimen, compared to the weekly doses of competitors like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which may increase patient adherence. The weight loss drug market is projected to grow at nearly 25% annually through 2035, indicating strong competitive potential for Pfizer. As alternatives emerge, the dynamics of the anti-obesity drug market may be shifting, impacting shares of incumbents like NVO and LLY.
Read More: Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
Eli Lilly (LLY) sees GLP-1 windfall, Honeywell (HON) divests unit
Eli Lilly (LLY) has reported significant financial benefits from its GLP-1 drug line, although specific figures are not detailed. Honeywell (HON) has made the strategic decision to divest a lower-margin unit, aiming to enhance overall profitability. This move could impact both companies' profit margins as LLY capitalizes on a high-demand market while HON restructures its operations. The market may see a shift as investors evaluate the potential growth of LLY and the implications of HON's divestiture.
Read More: Eli Lilly (LLY) sees GLP-1 windfall, Honeywell (HON) divests unit
GLP-1 Users Driving Retail Clothing Demand as Weight Loss Grows
Over 600,000 prescriptions for Novo Nordisk's Wegovy (NVO) were written by February 2023, indicating increased demand for weight loss drugs. Currently, nearly 13% of U.S. adults are on a GLP-1 medication, with adoption rates increasing from 11% in November 2024 to 16% in November 2025. Retailers are reporting a rise in customers seeking new clothing due to weight loss, with specific interest noted by services like Stitch Fix. Analysts predict that as accessibility improves, consumer spending on apparel is expected to grow significantly, particularly for smaller sizes.
Read More: GLP-1 Users Driving Retail Clothing Demand as Weight Loss Grows
GoodRx (GDRX) Offers Foundayo GLP-1 Medication for $149 Monthly
GoodRx (GDRX) has announced that it will offer the Foundayo GLP-1 medication starting at a price of $149 per month. This move provides a lower-cost option for patients seeking weight management treatments. The availability of this medication may impact the market for weight-loss pharmaceuticals by introducing competition. As healthcare costs continue to be a focus for consumers and providers, this pricing could influence purchasing decisions in the sector.
Read More: GoodRx (GDRX) Offers Foundayo GLP-1 Medication for $149 Monthly
Novo Nordisk (NVO) Wegovy Pill Launch Hits 600K Prescriptions
Novo Nordisk's (NVO) Wegovy pill, launched in early January, has seen over 600,000 prescriptions written within three months, including more than 3,000 in its first week. This surge reflects a growing demand for GLP-1 treatments as patients previously deterred by injection methods now gravitate towards the oral option. The pill is priced between $149 to $299 per month, which analysts attribute to its early success. Despite this positive start, Novo's stock price remains under pressure as competition from Eli Lilly's newly approved GLP-1 product, Foundayo, arises.
Read More: Novo Nordisk (NVO) Wegovy Pill Launch Hits 600K Prescriptions